Inhibitors of nucleoside metabolism

Details Inhibitors of nucleoside metabolism Inhibitors of nucleoside metabolism

2000-02-03

2001-05-08

Riley, Jezia (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S001000, C536S022100, C536S023100, C536S004100, C536S025300

Reexamination Certificate

active

06228847

ABSTRACT:

TECHNICAL FIELD
The invention relates to certain nucleoside analogues, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds and processes for preparing the compounds.
BACKGROUND OF THE INVENTION
Purine nucleoside phosphorylase (PNP) catalyses the phosphorolytic cleavage of ribo- and deoxyribonucleosides, for example, those of guanine and hypoxanthine to give the corresponding sugar-1-phosphate and guanine, hypoxanthine, or other purine bases.
Humans deficient in purine nucleoside phosphorylase (PNP) suffer a specific T-cell immunodeficiency due to an accumulation of dGTP and its toxicity to stimulated T lymphocytes. Because of this, inhibitors against PNP are immunosuppressive, and are active against T-cell malignancies. Clinical trials are now in progress using 9-(3-pyridylmethyl)-9-deazaguanine in topical form-against soriasis and in oral form for T-cell lymphoma and immunosuppression (BioCryst Pharmaceuticals, Inc). The compound has an IC
50
of 35 nM for the enzyme. In animal studies, a 50 mg/kg oral dose is required for activity in a contact sensitivity ear swelling assay in mice. For human doses, this would mean approximately 3.5 grams for a 70 kg human. With this inhibitor, PNP is difficult to inhibit due to the relatively high activity of the enzyme in blood and mammalian tissues.
Nucleoside and deoxynucleoside hydrolases catalyse the hydrolysis of nucleosides and deoxynucleosides. These enzymes are not found in mammals but are required for nucleoside salvage in some protozoan parasites. Purine phosphoribosyltransferases (PPRT) catalyze the transfer of purine bases to 5-phospho-&agr;-D-ribose-1-pyrophosphate to form purine nucleotide 5′-phosphates. Protozoan and other parasites contain PPRT which are involved in essential purine salvage pathways. Malignant tissues also contain PPRT. Some protozoan parasites contain purine nucleoside phosphorylases which also function in purine salvage pathways. Inhibitors of nucleoside hydrolases, purine nucleoside phosphorylases and PPRT can be expected to interfere with the metabolism of parasites and therefore be usefully employed against protozoan parasites. Inhibitors of PNP and PPRT can be expected to interfere with purine metabolism in malignant tissues and therefore be usefully employed against malignant tissues.
It is an object of the invention to provide pharmaceuticals which are very effective inhibitors-of PNP, PPRT and/or nucleoside hydrolases.


REFERENCES:
patent: 5985848 (1999-11-01), Furneaux et al.
patent: 6066722 (2000-05-01), Furneaux et al.

Affiliated with

Also associated with

Rating

Inhibitors of nucleoside metabolism does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of nucleoside metabolism, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of nucleoside metabolism will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2568888